Skip to main content


Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis

Fig. 1

Iguratimod inhibits ASC differentiation in vitro. af Human ASCs were differentiated from B cells by CpG/IL-2/IL-10 in the presence of vehicle (DMSO) or 10 μM iguratimod and checked at day 2, day 3, and day 5. FCM plots (a) and cumulative ASC frequencies (b, e) were shown (n = 3). IgG (c, f) and IgM (d, f) were detected in the supernatants (n = 3). bf were detected at day 5 of stimulation in triplicate. One representative of at least three independent experiments was shown (af). g Iguratimod inhibited ASC differentiation similarly by CD40L/IL-2/IL-21 (n = 5). Data were shown as mean ± SEM and analyzed by Student’s t test (bd, f) or one-way ANOVA with Bonferroni correction for multiple comparisons (e, f). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page